Myriad Genetics
MYGN
233 hedge funds and large institutions have $3.05B invested in Myriad Genetics in 2016 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 101 increasing their positions, 72 reducing their positions, and 28 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 72
14% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 28
0% more funds holding
Funds holding: 232 → 233 (+1)
21% less capital invested
Capital invested by funds: $3.86B → $3.05B (-$811M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
58% less call options, than puts
Call options by funds: $6.6M | Put options by funds: $15.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$23.3M |
| 2 |
D.E. Shaw & Co
New York
|
+$16.9M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$15.7M |
| 4 |
JIM
Jupiter Investment Management
London,
United Kingdom
|
+$10.6M |
| 5 |
Millennium Management
New York
|
+$9.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$202M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
-$71.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$67M |
| 4 |
SCM
Scopia Capital Management
New York
|
-$39.8M |
| 5 |
FMA
Fiduciary Management Associates
Chicago,
Illinois
|
-$17.4M |
MYGN Hedge Fund Activity: Q1 2016 in Review
233 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q1 2016, worth a combined $3.05B — down 21% from $3.86B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new MYGN positions and 28 closed out — a net gain of 4 holders — while 101 added to existing stakes and 72 trimmed.
The largest buyer was Iridian Asset Management, adding an estimated $23.3M. The largest seller was Capital World Investors, cutting an estimated $202M.
- 233 institutional investors held Myriad Genetics (MYGN) as of Q1 2016, up from 232 in Q4 2015.
- Funds reported $3.05B of Myriad Genetics stock for Q1 2016, down 21% quarter-over-quarter.
- 32 funds opened new Myriad Genetics positions in Q1 2016 and 28 closed out, a net change of +4 holders.
- The largest Myriad Genetics buyer in Q1 2016 was Iridian Asset Management, an estimated $23.3M added.
- The largest Myriad Genetics seller in Q1 2016 was Capital World Investors, an estimated $202M sold.
Based on aggregated 13F filings for Q1 2016.